Section 1

Diagnostic criteria for PoTS

PoTS is diagnosed on clinical grounds using standardised criteria. There is no single biomarker. The Heart Rhythm Society (HRS) and European Heart Rhythm Association (EHRA) consensus definition requires all four of the following:[1]

Criterion Detail Notes
Heart rate rise ≥30 bpm Within 10 minutes of standing or 70° head-up tilt. ≥40 bpm in adolescents aged 12–19. HR typically exceeds 120 bpm. Rate of rise in first 30 seconds may be diagnostically useful.
No orthostatic hypotension Systolic BP drop <20 mmHg, diastolic drop <10 mmHg within 3 minutes of standing. If OH is present, the diagnosis is orthostatic hypotension, not PoTS (though co-occurrence is described).
Symptoms for ≥3 months Symptoms of orthostatic intolerance: dizziness, palpitations, presyncope, fatigue, cognitive dysfunction. Shorter duration may still warrant evaluation, particularly post-COVID or post-viral.
No alternative explanation Exclude anaemia, dehydration, thyroid disease, adrenal insufficiency, medication effect (e.g. vasodilators). Basic bloods (FBC, TFTs, U&E, glucose, ferritin) are appropriate first-line investigations.

Key distinction: PoTS is characterised by tachycardia without significant hypotension. Blood pressure may actually rise in the hyperadrenergic subtype. A standing systolic rise >10 mmHg above supine value is a clue to hyperadrenergic PoTS.[2]

Subtypes of PoTS

Subtype Mechanism Clues Treatment implication
Neuropathic Partial sympathetic denervation of lower limb vessels causing blood pooling Most common. Often young women. May have skin changes (livedo, sweating asymmetry). Volume expansion, compression, fludrocortisone
Hyperadrenergic Excess sympathetic activity, elevated standing noradrenaline (>600 pg/mL) Tremor, anxiety, palpitations, hypertension on standing. Often familial. Low-dose beta-blocker, clonidine — avoid fludrocortisone
Hypovolaemic Reduced plasma volume or total blood volume Often responds well to saline infusion. Low aldosterone/renin ratios. Aggressive fluid/salt loading, desmopressin in selected cases
Post-COVID / post-viral Likely multifactorial: autoimmune, neurological, hypovolaemic Onset within 3–6 months of COVID-19 illness. May have additional ME/CFS features. Graduated exercise rehabilitation; avoid aggressive deconditioning protocols
Section 2

Active stand test protocol

The active stand test (also called the NASA lean test when performed against a wall) is a reliable bedside screening tool that can be performed in primary care without specialist equipment. It has good sensitivity for PoTS when performed correctly.[3]

Safety note: Ensure the patient is not at high risk of syncope before performing. Have the patient sit or lie down if they feel faint. Do not perform if recent syncope within 48 hours or significant bradycardia at rest (<50 bpm).

1

Preparation

Ensure patient has not eaten a large meal, taken stimulants (caffeine), or exercised strenuously within 2 hours. Patient should be adequately hydrated. Ask about recent fluid and salt intake.

2

Supine baseline (10 minutes)

Patient lies flat for at least 10 minutes. Record heart rate (HR) and blood pressure (BP) at 5 and 10 minutes. Use the 10-minute reading as your baseline.

3

Active standing

Patient stands actively (not tilted passively). Record HR and BP at:

  • 1 minute of standing
  • 3 minutes of standing
  • 5 minutes of standing
  • 10 minutes of standing (if tolerated)
4

Symptom recording

Ask the patient to rate symptoms (dizziness, palpitations, chest tightness, brain fog, nausea) at each time point on a 0–10 scale. Document any near-presyncope or early termination.

5

Interpretation

A rise of ≥30 bpm (≥40 bpm in adolescents) that is sustained, in the presence of symptoms, is consistent with PoTS. Record the maximum HR rise and the time at which it occurred. A negative test does not exclude PoTS — consider formal tilt table testing if clinical suspicion remains high.

Practical tip: A pulse oximeter with continuous HR display is sufficient for monitoring. Automated BP cuffs are adequate. Document whether symptoms were reproduced during the test — this is clinically as important as the numbers.[3]

Section 3

Prescribing in PoTS

Non-pharmacological management should always be initiated first and continued alongside any medication. No drug is licensed specifically for PoTS in the UK. All pharmacological treatments are used off-label and should be initiated with appropriate patient counselling.[4]

Off-label use: All medications listed below are used outside their licensed indications for PoTS. Ensure this is documented in the patient record and that shared decision-making is followed. Consider specialist initiation for ivabradine, fludrocortisone, and midodrine.

Non-pharmacological management — first line for all patients

Intervention Target / Detail
Fluid intake 2–3 litres per day. Bolus water (500 mL rapidly) acutely reduces tachycardia via the gastric pressor reflex. Recommend consistent daily intake.
Salt intake 8–10 g sodium chloride per day (or 3–5 g sodium), unless contraindicated (hypertension, renal disease). Salt tablets may be used if dietary sources are insufficient.
Compression garments Waist-high compression (20–30 mmHg). Abdominal binders are particularly effective at reducing splanchnic pooling. Must be worn standing.
Head-of-bed elevation Raise the head of the bed by 10–15 cm (6–8 inches). Reduces nocturnal diuresis and helps maintain plasma volume.
Exercise rehabilitation Evidence-based graded programme. Begin with recumbent exercises (swimming, rowing, cycling) before upright activity. Avoid prolonged standing or high-intensity upright exercise initially.
Trigger avoidance Avoid prolonged standing, hot environments, large carbohydrate-heavy meals, alcohol, and dehydration. Teach counter-manoeuvres (leg crossing, squatting, muscle tensing).

Pharmacological options

Drug Line Dose (typical) Mechanism Cautions / notes
Ivabradine 1st line 2.5–7.5 mg BD If channel blocker — reduces HR without affecting BP or contractility Preferred in patients where beta-blockers are poorly tolerated. Avoid in AF. Unlicensed for PoTS. Specialist initiation preferred.[4]
Propranolol (low dose) 1st line 10–20 mg BD–TDS Beta-1/2 blockade — reduces HR and adrenergic drive Preferred in hyperadrenergic subtype. Avoid in asthma. May worsen fatigue. Low dose is key — higher doses often poorly tolerated.[4]
Fludrocortisone 2nd line 50–200 mcg od Mineralocorticoid — promotes sodium and water retention, expanding plasma volume Avoid in hyperadrenergic PoTS (may worsen hypertension). Monitor BP, potassium, and oedema. Not appropriate if concomitant hypertension.[5]
Midodrine 2nd line 2.5–10 mg TDS Alpha-1 agonist — increases venous tone and peripheral resistance Do not take within 4 hours of lying down (supine hypertension risk). Avoid in urinary retention. Most useful in neuropathic subtype.[5]
Pyridostigmine Specialist 30–60 mg BD–TDS Acetylcholinesterase inhibitor — enhances cholinergic tone, reduces standing HR Evidence from small RCTs. Well tolerated. GI side effects common. May be useful when other agents have failed.[6]
Desmopressin (DDAVP) Specialist 100–200 mcg nocte V2 receptor agonist — reduces nocturnal diuresis, maintains volume Short-term use only. Risk of hyponatraemia — monitor sodium. Useful in hypovolaemic subtype. Specialist initiation only.

Prescribing sequence: Begin with non-pharmacological measures for 4–8 weeks before adding medication. If pharmacotherapy is required, ivabradine or low-dose propranolol are the most commonly used first-line agents in UK practice. Combination therapy may be needed in refractory cases.[4]

Section 4

Referral guidance

Many patients with PoTS can be managed in primary care once the diagnosis is established. Referral is appropriate in the following circumstances.

When to refer

Consider referral to Cardiology or Autonomic Neurology if any of the following apply:

↓

Clinical indications

Diagnostic uncertainty · Syncope · Abnormal ECG · Suspected hyperadrenergic subtype · Failed first-line management · Significant functional impairment · Adolescent patients · Suspected secondary cause

Management indications

Considering specialist medications (ivabradine, midodrine, fludrocortisone) · Requirement for tilt table testing · Suspected coexisting autoimmune dysautonomia · Pregnancy with PoTS

↓

In Scotland: refer to Cardiology (arrhythmia / syncope clinic)

Most PoTS patients are managed by Cardiology in Scotland. Autonomic neurology input is available at specialist centres for complex cases. Discuss with your regional cardiology team if uncertain.

Referral letter template

Referral letter template Cardiology / Autonomic clinic — PoTS query
Dear Colleague, Re: [Patient name], DOB [date], CHI [number] Thank you for seeing this [age]-year-old [sex] who has been experiencing symptoms consistent with Postural Orthostatic Tachycardia Syndrome. Presenting symptoms: [e.g. Dizziness, palpitations, and marked fatigue on standing for approximately [X] months. Symptoms are significantly impacting daily activities including work/school.] Active stand test findings: Supine HR: [X] bpm · Standing HR at 10 min: [X] bpm · Rise: [X] bpm Supine BP: [X/X] · Standing BP at 10 min: [X/X] Symptoms reproduced: [Yes/No — describe] Investigations to date: FBC, U&E, TFTs, ferritin — [results]. ECG — [findings]. [Any other relevant investigations] Current management: Fluid and salt loading advised. Compression garments recommended. [Any medication initiated]. I would be grateful for your assessment, confirmation of diagnosis, consideration of formal tilt table testing if appropriate, and advice on further management. Yours sincerely, [Your name, GMC number, practice/hospital]
Download referral template (Word)
Section 5

Comorbidity recognition

PoTS frequently coexists with other conditions. Recognising these comorbidities improves diagnostic accuracy, avoids missed diagnoses, and has direct management implications.[7]

Hypermobile EDS (hEDS)

Overlap: ~50% of PoTS patients

Joint hypermobility contributes to blood pooling and autonomic dysfunction. hEDS should be considered in all PoTS patients with joint pain, skin laxity, or a history of recurrent dislocations.

  • Beighton score ≥5 (or ≥4 in those >50 years)
  • Systemic features: skin hyperextensibility, atrophic scarring
  • Joint pain, recurrent subluxations
  • Refer to Rheumatology or Genetics if suspected

ME/CFS

Overlap: ~25–50% of PoTS patients

Significant symptomatic overlap with PoTS including fatigue, cognitive dysfunction, and post-exertional malaise. Post-exertional malaise (PEM) is the defining feature of ME/CFS and should be specifically asked about.

  • Ask directly about PEM — worsening symptoms 12–48 h after activity
  • Graded exercise therapy is contraindicated in ME/CFS
  • Management must be adapted accordingly
  • Refer to ME/CFS specialist clinic if suspected

Mast Cell Activation Syndrome (MCAS)

Overlap: ~30% of PoTS patients

MCAS can trigger autonomic symptoms via mediator release. Consider in patients with flushing, urticaria, anaphylaxis-like episodes, or gastrointestinal symptoms alongside PoTS.

  • Serum tryptase (ideally measured during a symptomatic episode)
  • 24-hour urine prostaglandin D2 or histamine
  • Trial of antihistamines (H1 and H2) may be diagnostic
  • Refer to Allergy/Immunology if suspected

Autoimmune dysautonomia

Overlap: ~10–15% of PoTS patients

Antibodies against adrenergic or muscarinic receptors have been identified in a subgroup of PoTS patients. Consider if atypical features, systemic autoimmune disease, or subacute onset.

  • ANA, anti-dsDNA, anti-Ro/La
  • Anti-ganglionic AChR antibody (specialist test)
  • Adrenergic receptor antibodies (research use)
  • Refer to Autonomic Neurology or Immunology
Section 6

Evidence summary

The evidence base for PoTS treatments is growing but remains predominantly based on small RCTs and observational studies. The following summarises key interventions by evidence strength.

A

Exercise training (recumbent-based) — strong evidence

Fu et al. (2011) demonstrated significant improvements in plasma volume, VO₂ max, and orthostatic tolerance with a structured 3-month exercise programme. Exercise is the only intervention with evidence of disease modification rather than symptom control.[8]

A

Volume expansion (fluid and salt) — strong evidence

Rapid oral water ingestion (500 mL) produces a measurable pressor response within 5–15 minutes. High-sodium diet reduces standing HR and improves symptom burden in multiple studies.[1]

B

Ivabradine — moderate evidence

Several small RCTs and observational studies demonstrate reduction in standing HR and symptomatic improvement. McDonald et al. (2021) showed superior symptom relief over propranolol in a crossover RCT in adolescents.[4]

B

Low-dose propranolol — moderate evidence

Raj et al. demonstrated that low-dose propranolol (10–20 mg) significantly reduced standing HR and palpitations compared to placebo in a double-blind RCT. Higher doses produced more side effects without additional benefit.[4]

B

Compression garments — moderate evidence

Abdominal compression reduces splanchnic venous pooling. Waist-high compression stockings (20–30 mmHg) reduce standing HR by approximately 10 bpm in controlled studies.[1]

C

Fludrocortisone, midodrine, pyridostigmine — limited evidence

Widely used in clinical practice based on physiological rationale and expert opinion. Controlled trial data for each are limited. The CHOP POTS study (paediatric) and several adult observational series support their use in refractory cases.[5,6]

Key references

[1] Sheldon RS et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of POTS. Heart Rhythm. 2015;12(6):e41–63.

[2] Raj SR et al. Postural orthostatic tachycardia syndrome (POTS): priorities for POTS research. Auton Neurosci. 2013;215:1–5.

[3] Stewart JM et al. The standing test for diagnosis of POTS. J Pediatr. 2012;160(1):117–22.

[4] McDonald C et al. Ivabradine in postural orthostatic tachycardia syndrome: a randomized crossover trial. Heart Rhythm. 2021;18(7):1114–22.

[5] Raj SR. Postural tachycardia syndrome (POTS). Circulation. 2013;127(23):2336–42.

[6] Kanjwal K et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol. 2011;34(6):750–5.

[7] Benarroch EE. Postural tachycardia syndrome: a heterogeneous and multifactorial disorder. Mayo Clin Proc. 2012;87(12):1214–25.

[8] Fu Q et al. Sustained sympathetic activation during exercise in postural tachycardia syndrome. J Am Coll Cardiol. 2011;58(5):536–45.